Institute of Cardiovascular and Medical Sciences

Prof Mandy Maclean

  • Professor of Pulmonary Pharmacology (Institute of Cardiovascular and Medical Sciences)
  • Dean of Graduate Studies (MVLS College Senior Management)

telephone: 01413304768
email: Mandy.MacLean@glasgow.ac.uk


Prof Margaret (Mandy) R MacLean directs a research group studying the pharmacology of pulmonary hypertension. The group has a particular interest in the role of serotonin in the pathobiology of pulmonary hypertension.

Research:

Theme:

Jump to: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2003 | 2002 | 2001
Number of items: 29.

2013

Ciuclan, L. et al. (2013) Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression. American Journal of Respiratory and Critical Care Medicine, 187 (1). pp. 78-89. ISSN 1073-449X (doi:10.1164/rccm.201206-1028OC)

White, K. et al. (2013) Activity of the estrogen metabolising enzyme Cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation . ISSN 0009-7322 (doi:10.1161/CIRCULATIONAHA.111.062927) (In Press)

2012

Baranowska-Kuczko, M., MacLean, M.R., Kozłowska, H., and Malinowska, B. (2012) Endothelium-dependent mechanisms of the vasodilatory effect of the endocannabinoid, anandamide, in the rat pulmonary artery. Pharmacological Research, 66 (3). pp. 251-259. ISSN 1043-6618 (doi:10.1016/j.phrs.2012.05.004)

Caruso, P. et al. (2012) A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circulation Research, 111 (3). pp. 290-300. ISSN 0009-7330 (doi:10.1161/CIRCRESAHA.112.267591)

McDonald, R.A., Hata, A., MacLean, M.R., Morrell, N.W., and Baker, A.H. (2012) MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling. Cardiovascular Research, 93 (4). pp. 594-604. ISSN 0008-6363 (doi:10.1093/cvr/cvr299)

Morecroft, I., White, K., Caruso, P., Nilsen, M., Loughlin, L., Alba, R., Reynolds, P.N., Danilov, S.M., Baker, A.H., and MacLean, M.R. (2012) Gene therapy by targeted adenovirus-mediated knockdown of pulmonary endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension. Molecular Therapy, 20 (8). pp. 1516-1528. ISSN 1525-0016 (doi:10.1038/mt.2012.70)

2011

Dempsie, Y., Nilsen, M., White, K., Mair, K., Loughlin, L., Ambartsumian, N., Rabinovitch, M., and MacLean, M. (2011) Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females. Respiratory Research, 12 (1). p. 159. ISSN 1465-9921 (doi:10.1186/1465-9921-12-159)

Morecroft, I., Doyle, B., Nilsen, M., Kolch, W., Mair, K., and MacLean, M.R. (2011) Mice lacking the Raf-1 kinase inhibitor protein exhibit exaggerated hypoxia-induced pulmonary hypertension. British Journal of Pharmacology, 163 (5). pp. 948-963. ISSN 0007-1188 (doi:10.1111/j.1476-5381.2011.01305.x)

White, K., Dempsie, Y., Nilsen, M., Wright, A.F., Loughlin, L., and MacLean, M.R. (2011) The serotonin transporter, gender, and 17  oestradiol in the development of pulmonary arterial hypertension. Cardiovascular Research, 90 (2). pp. 373-382. ISSN 0008-6363 (doi:10.1093/cvr/cvq408)

White, K., Loughlin, L., Maqbool, Z., Nilsen, M., McClure, J., Dempsie, Y., Baker, A.H., and MacLean, M.R. (2011) The serotonin transporter, gender and hypoxia: Microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH. Physiological Genomics, 43 (8). pp. 417-437. ISSN 1094-8341 (doi:10.1152/physiolgenomics.00249.2010)

2010

Caruso, P. et al. (2010) Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arteriosclerosis, Thrombosis and Vascular Biology, 30 (4). pp. 716-723. ISSN 1079-5642 (doi:10.1161/ATVBAHA.109.202028)

Morecroft, I., Pang, L., Baranowska, M., Nilsen, M., Loughlin, L., Dempsie, Y., Millet, C., and MacLean, M. R. (2010) In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension. Cardiovascular Research, 85 (3). pp. 593-603. ISSN 0008-6363 (doi:10.1093/cvr/cvp306)

Morecroft, I., Pang, L., Baranowska, M., Nilsen, M., Loughlin, L., Dempsie, Y., Millet, C., and MacLean, M.R. (2010) In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension. Cardiovascular Research, 85 (3). pp. 593-603. ISSN 0008-6363 (doi:10.1093/cvr/cvp306)

Kelland, N.F., Bagnall, A.J., Morecroft, I., Gulliver-Sloan, F.H., Dempsie, Y., Nilsen, M., Yanagisawa, M., MacLean, M.R., Kotelevtsev, Y.V., and Webb, D.J. (2010) Endothelial ET limits vascular remodelling and development of pulmonary hypertension during hypoxia. Journal of Vascular Research, 47 (1). pp. 16-22. ISSN 1018-1172 (doi:10.1159/000231717)

MacLean, M.R., and Dempsie, Y. (2010) The serotonin hypothesis of pulmonary hypertension revisited. In: Membrane Receptors, Channels and Transporters in Pulmonary Circulation. Humana Press, pp. 309-322. ISBN 978-1-60761-499-9

White, K., Dempsie, Y., Nilsen, M., Wright, A.F., Loughlin, L., and MacLean, M.R. (2010) The serotonin transporter, gender and 17  estradiol in the development of pulmonary arterial hypertension. Cardiovascular Research, 90 (2). pp. 373-382. ISSN 0008-6363 (doi:10.1093/cvr/cvq408)

2009

Morecroft, I., Murray, A., Nilsen, M., Gurney, A.M., and MacLean, M.R. (2009) Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. British Journal of Pharmacology, 157 (7). pp. 1241-1249. ISSN 0007-1188 (doi:10.1111/j.1476-5381.2009.00283.x)

Page, C., and MacLean, M.R. (2009) Novel pharmacological approaches to airway and pulmonary vascular disease. Current Opinion in Pharmacology, 9 (3). pp. 229-230. ISSN 1471-4892 (doi:10.1016/j.coph.2009.04.003)

MacLean, M.R., and Dempsie, Y. (2009) Serotonin and pulmonary hypertension—from bench to bedside? Current Opinion in Pharmacology, 9 (3). pp. 281-286. ISSN 1471-4892 (doi:10.1016/j.coph.2009.02.005)

Mair, K.M., MacLean, M.R., Morecroft, I., Dempsie, Y., and Palmer, T.M. (2009) Novel interactions between the 5-HT transporter, 5-HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts. British Journal of Pharmacology, 155 (4). pp. 606-616. ISSN 0007-1188 (doi:10.1038/bjp.2008.310)

Mair, K.M., MacLean, M.R., Morecroft, I., Dempsie, Y., and Palmer, T.M. (2009) Novel interactions between the 5-HT transporter, 5-HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts. British Journal of Pharmacology, 155 (4). pp. 606-616. ISSN 0007-1188 (doi:10.1038/bjp.2008.310)

Morrell, N.W. et al. (2009) Cellular and molecular basis of pulmonary arterial hypertension. Journal of the American College of Cardiology, 54 (1 Supp). S20-S31. ISSN 0735-1097 (doi:10.1016/j.jacc.2009.04.018)

2008

Dempsie, Y. et al. (2008) Converging Evidence in Support of the Serotonin Hypothesis of Dexfenfluramine-Induced Pulmonary Hypertension With Novel Transgenic Mice. Circulation, 117 (22). pp. 2928-2937. ISSN 0009-7322 (doi:10.1161/CIRCULATIONAHA.108.767558)

Dempsie, Y., and MacLean, M.R. (2008) Pulmonary hypertension: therapeutic targets within the serotonin system. British Journal of Pharmacology, 155 (4). pp. 455-462. ISSN 0007-1188 (doi:10.1038/bjp.2008.241)

2007

MacLean, M. (2007) Pulmonary hypertension and the serotonin hypothesis: where are we now? International Journal of Clinical Practice, 61 (S156). pp. 27-31. ISSN 1368-5031 (doi:10.1111/j.1742-1241.2007.01497.x)

2003

Murray, F., MacLean, M.R., and Pyne, N.J. (2003) An assessment of the role of the inhibitory gamma subunit of the retinal cyclic GMP phosphodiesterase and its effect on the p42/p44 mitogen-activated protein kinase pathway in animal and cellular models of pulmonary hypertension. British Journal of Pharmacology, 138 . pp. 1313-1319. ISSN 0007-1188 (doi:10.1038/sj.bjp.0705190)

2002

Fisher, C, MacLean, M, Morecroft, I, Seed, A, Johnston, F, Hillier, C, and McMurray, J (2002) Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart? Circulation, 106 . pp. 292-295. (doi:10.1161/01.CIR.0000025630.05387.45)

Murray, F., MacLean, M.R., and Pyne, N.J. (2002) Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. British Journal of Pharmacology, 137 (8). pp. 1187-1194. (doi:10.1038/sj.bjp.0704984)

2001

Welsh, DJ, Peacock, AJ, MacLean, M, and Harnett, M (2001) Chronic hypoxia induces constitutive p38 mitogen-activated protein kinase activity that correlates with enhanced cellular proliferation in fibroblasts from rat pulmonary but not systemic arteries. American Journal of Respiratory and Critical Care Medicine, 164 . pp. 282-289. ISSN 1073-449X

This list was generated on Fri May 3 04:55:59 2013 BST.

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Excellence with Impact - Sparking Impact Award
    Biotechnology and Biological Sciences Research Council
    2013 - 2014
     

Editorial Board

  • 2009 - ongoing: Faculty 1000 - Biology-section head-Respiratory Pharmacology
  • 2008 - ongoing: Current Opinion in Pharmacology - Section Editor-Respiratory Section
  • 1999 - 2003: British Journal of Pharmacology
  • 1999 - ongoing: Pulmonary Pharmacology & Therapeutics

Grant Advisory Board

  • 2010 - ongoing: BBSRC - Animals Advisory Group
  • 2009 - ongoing: BBSRC - Member of Strategic LoLa Committee
  • 2009 - 2012: BBSRC - Deputy Chair Grant Committee A
  • 2007 - ongoing: BBSRC - Member of BBSRC Animal Physiology Working Group
  • 2007 - 2009: BBSRC - Member of Animal Sciences Committee
  • 2004 - ongoing: IUPHAR - Nomenclature Committee for Urotensin-II

Invited International Presentations

  • 2010: Keystone, Colorado - Keystone Symposium on Hypoxia: Molecular Mechanisms
  • 2008: Colorado, USA - Grover Conference on PAH. Winner of Estelle Grover Award and Plenary Lecturer. http://www.thoracic.org/sections/about-ats/assemblies/pc/grover.html
  • 2008: Orange County, CA, USA - 4th World Symposium on Pulmonary Hypertension. Working Group Member and Presenter on the Serotonin Hypothesis. Basic Science?Cellular & Molecular Basis of PAH
  • 2008: The Royal Society, London, UK - Invited Speaker - Third John Vane Memorial Symposium - Prostacyclin Science and Pulmonary Vascular Disease
  • 2007: San Francisco, USA - American Thoracic Society Congress. Speaker and Chair on Mini-symposium 'Cellular and molecular mechanisms of pulmonary hypertension: new insights'
  • 2007: Leeds, England - Meeting of Café Scientifique Organisers-Leading panel discussion with Lord Rees (Royal Society) and Daniel Glaser Wellcome Trust)
  • 2007: Nice, France - 12th Annual Meeting of the European Council for Cardiovascular Research. Keynote Speaker: Pulmonary Hypertension
  • 2007: Nice, France - 12th Annual Meeting of the European Council for Cardiovascular Research. Keynote Speaker: Pulmonary Hypertension
  • 2007: Crieff, Scotland - James Black Conference on 'Cutting Edge Concepts in Lung Pharmacology'. Co-organiser, chair and speaker
  • 2007: London, England - 1st International Meeting on Pulmonary Hypertension in Childhood. Invited Speaker. Royal College of Physicians
  • 2006: San Diego, California, USA - Invited speaker at American Thoracic Society International Conference - Postgraduate Course on 'Cellular Biology of Hypoxia'. 'highlighted abstract' awarded.
  • 2006: Prague, Czech Republic - Physiological Society International Workshop on 'Cardiopulmonary Function in Health and Disease'
  • 2006: Dublin, Ireland - The Associations of Pulmonary Hypertension Centres of Great Britain and Ireland - Speaker at 2nd International Workshop on pulmonary hypertension
  • 2006: Phuket, Thailand - Annual meeting of the Pharmacological and Theraputic Society of Thailand - 13th Dr. Chiravat's Memorial Lecture
  • 2005: American Thoracic Society - Oral presentation.
  • 2005: European Respiratory Society - Scientific Year in Review. This symposium presents some of the major advances in understanding the biological and molecular mechanisms underlying respiratory disorders. Title of talk: Serotonin transporter genes, pulmonary haemodynamics and pulmonary hype
  • 2004: Baltimore, USA - The Pulmonary vasculature in lung diisease (6 speakers) American Pulmonary Research Group
  • 2004: Philladelphia, USA - Johnson and Johnson, USA. Spring House Seminar (1 speaker)
  • 2004: American Thoracic Society - Two selected oral presentations
  • 2004: Orlando, Florida - Presenter of two talks at mini-symposium on the interactions between serotonin and the BMPR2 system. (6 speakers) American Thoracic Society

Prizes, Awards and Distinctions

  • 2010: BBSCR Masters Studentships Priority Area Training Awards. PI on application from Faculty of Biomedical and Life Sciences for integrative in vivo biology/systems biology training. Awarded 15 MRes studentships. 2010-2013
  • 2010: MBE for Services to Science
  • 2010: Royal Society Wolfson - Research Merit Award for research into the role of serotonin in pulmonary hypertension
  • 2009: BBSRC Deputy Chair Grant Committee A
  • 2009: MRC Capacity Building Studentship Competition 2009 and 2010. PI on application from Faculty of Biomedical and Life Sciences and Faculty of Medicine for in vivo training. Awarded 6 x 1+3 PhD studentships: £493,860
  • 2008: Estelle Grover Lecture Award - Awarded by the American Thoracic Society in recognition of international contribution to research into pulmonary arterial hypertension
  • 2006: Principle Investigator on Capacity Building consortium training award in Integrative Mammalian Biology awarded to Glasgow/Strathclyde University. £2.9M (Funded by Pfizer, GSK, AstraZenica, BPS, DTI, BBSRC and MRC), 2006-2011.
  • 2005: Elected Fellow of British Pharmacological Society (F.B.Pharmacol.S.) in recognition of commitment and distinction in Pharmacology through scholarship and service to the Society.

Professional Learned Society

  • 2006 - 2008: British Pharmacological Society - Vice-President (Meetings)
  • 2001 - ongoing: International Union of Pharmacology - Receptor Nomenclature Committee
  • 2001 - ongoing: American Thoracic Society - -member of 'pulmonary circulation programme committee' and 'pulmonary circulation planning committee'
  • 2000 - ongoing: American Heart Association - Communications Committee 2000-03.
  • 1998 - ongoing: European Respiratory Society
  • 1992 - ongoing: British Society for Cardiovascular Research - Member
  • 1991 - ongoing: Physiological Society - Member
  • 1988 - ongoing: British Pharmacological Society - Meetings Committee 2001-06. Scientific Interest Group on Cardiovascular and Pulmonary Pharmacology 2003-ongoing.